Mar. 27 at 9:43 PM
$SSKN Strata Skin Sciences reports Q4 EPS (
$1.18), consensus (40c)
Reports Q4 revenue $
$9.6M, consensus
$8.98M...Net loss for the fourth quarter of 2024 was
$4.5 M or EPS of negative
$1.18 per basic and diluted common share, as compared to a net loss of
$3.8 M , or EPS of negative
$1.09 per basic and diluted common share, in the fourth quarter of 2023. Cash, cash equivalents, and restricted cash at December 31 were
$8.6M . "2024 was a year of execution for STRATA. Our fourth quarter results highlight the success we are having in implementing our strategy to shift our existing installed base from underperforming centers to more productive ones while utilizing our DTC and service model to help our customers succeed," commented STRATA's President and CEO Dr. Dolev Rafaeli.
"We have reduced XTRAC devices in our domestic installed base to 864, from 923 at the prior year end, resulting in average revenue per device increasing to
$5,906 in the fourth quarter of 2024, up from
$5,555 in the prior-year period, representing an increase of 6%. At the same time, our operating margins, adjusted for non-cash impairment charges in both periods, improved by 950 bps compared to the fourth quarter of 2023. On a full-year basis, our non-GAAP adjusted EBITDA, including the adjustment for the
$1.8 million accrual we discussed last quarter, improved to
$2.2 million versus
$1.0 million in the prior year.
"With regard to our international markets, we have seen significant traction, with particular strength in the Equipment segment. During the fourth quarter, international sales increased to
$4.1 million, which represents a sequential increase of 27% over the prior quarter and 41% over the prior year period, with the international portion of the Equipment segment up 45% over the fourth quarter of 2023," concluded Dr, Rafaeli.
